Scinai to Debate Oral Therapies' Role in Reshaping Biologics Landscape
Event summary
- Scinai Immunotherapeutics will lead a roundtable at the 7th Dermatology Drug Development Summit Europe on May 22, 2026 in Amsterdam.
- The discussion will focus on whether oral peptide and small molecule therapies can complement or displace injectable biologics in dermatology.
- CEO Amir Reichman and R&D Director Dr. Meital Portugal will explore clinical, commercial, and strategic implications of oral therapies.
- Scinai is advancing a pipeline of immunology therapies licensed from Max Planck Society and PinCell S.r.l.
The big picture
The debate reflects a broader industry shift toward evaluating not just therapeutic efficacy but also modality selection, treatment persistence, and patient convenience. Scinai's participation underscores the strategic importance of oral therapies in reshaping the immunology landscape, potentially influencing physician confidence, payer dynamics, and lifecycle management of biologic franchises. The discussion comes as biopharmaceutical companies increasingly explore next-generation therapeutic modalities beyond traditional biologics.
What we're watching
- Therapeutic Disruption
- How oral therapies will affect treatment sequencing in dermatology and immunology.
- Modalities Competition
- Whether oral cytokine blockers can achieve biologic-competitive efficacy and durability.
- Industry Evolution
- The pace at which scientific innovation shifts focus from efficacy to convenience and accessibility.
Related topics